FREMONT, Calif., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a
clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our
proprietary ADAM technology, announced today that Mr. Kenneth R. Greathouse has been appointed to the Board of Directors.
"We are pleased to have Ken joining us at such an important stage for the Company," commented John Walker, Chief Executive
Officer and Chairman of the Board. “Ken’s commercial experience in the field of neurology will provide Zosano with leadership
and insight as we progress M207 towards the market.”
“I am pleased to join the Board,” commented Mr. Greathouse. “I look forward to working with the management team and Board
as our lead program progresses towards an NDA filing and, if approved, towards commercialization.”
Kenneth R. Greathouse is a seasoned pharmaceutical executive with over 40 years of experience in sales, marketing, business
development and commercial operations. He is the co-founder of several successful drug development companies, including
Manchester Pharmaceuticals which was sold to Retrophin Inc. in 2014. He began his career with Lederle Laboratories where for
over 18 years he held a number of sales and marketing positions of increasing responsibility. He joined Athena Neurosciences
in 1993 and continued with Elan Pharmaceuticals after the acquisition of Athena. After a two year tenure at Boron LePore and
Associates as Vice President and General Manager of Contract Sales, he joined Questcor as Senior Vice President, Commercial
Operations. Since leaving Questcor, Mr. Greathouse has co-founded and served as CEO of Argent Development Group LLC,
Melbourne Laboratories LLC, Valcrest Pharmaceuticals LLC, and Hesperian BioPharma LLC, in addition to Manchester Pharmaceuticals
LLC.
About Zosano Pharma
Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing rapid systemic administration of
therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray, or ADAM technology. The Company recently
announced positive results from our ZOTRIP study that evaluated M207, which is our proprietary formulation of zolmitriptan
delivered via our ADAM technology, as an acute treatment for migraine. Zosano is focused on developing products where rapid
administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, for
markets where patients remain underserved by existing therapies. The Company anticipates that many of its current and future
development programs may enable the Company to utilize a regulatory pathway that would streamline clinical development and
accelerate the path towards commercialization. Learn more at www.zosanopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding the timing of expected clinical development milestones,
sufficiency of our capital resources and need for future funding and other future events and expectations. Readers are urged to
consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and
uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are
safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other
risks and uncertainties described under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K..
Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way
guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking
statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and
Zosano assumes no obligation to update any such forward-looking statements.
Zosano Contact:
Georgia Erbez
Chief Business Officer and
Chief Financial Officer
510-745-1200
